Can a Triple-Drug combo tame acute myeloid leukemia in frail patients?

This phase 2 trial is testing whether adding an experimental drug called MAX-40279 to the standard combination of venetoclax and azacitidine can help treat newly diagnosed acute myeloid leukemia (AML) in people who are not healthy enough for intensive chemotherapy. The study includes adults aged 65 or older, or younger adults with conditions like heart or lung problems that make standard chemo too risky. Researchers are looking at safety, the right dose, and how well the combination works at achieving remission.